Authors Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Focus on cutaneous and uveal melanoma specificities.Authors Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Focus on cutaneous and uveal melanoma specificities.Authors Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C
Genes & development May 2017
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.Authors Bonet C, Luciani F, Ottavi JF, Leclerc J, Jouenne FM, Boncompagni M, Bille K, Hofman V, Bossis G, Marco de Donatis G, Strub T, Cheli Y, Ohanna M, Luciano F, Marchetti S, Rocchi S, Birling MC, Avril MF, Poulalhon N, Luc T, Hofman P, Lacour JP, Davidson I, Bressac-de Paillerets B, Ballotti R, Marine JC, Bertolotto C
Journal of the National Cancer Institute Apr 2017
Deregulated MITF sumoylation: A route to melanoma.Authors Ballotti R, Bertolotto C
Molecular & cellular oncology Jan 2017
FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells.Authors Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, Pawlikowska P, Karmous-Benailly H, Ballotti R, Rosselli F, Bertolotto C
Scientific reports Nov 2016
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.Authors Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J
EMBO molecular medicine Oct 2016
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.Authors Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S
Cancer cell Aug 2016
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.Authors Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, , Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B
Nature Mar 2016
Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.Authors Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, Ballotti R, Rocchi S
Cell discovery Oct 2015